Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.
Keller M, Rohlf K, Glotzbach A, Leonhardt G, Lüke S, Derksen K, Demirci Ö, Göçener D, AlWahsh M, Lambert J, Lindskog C, Schmidt M, Brenner W, Baumann M, Zent E, Zischinsky ML, Hellwig B, Madjar K, Rahnenführer J, Overbeck N, Reinders J, Cadenas C, Hengstler JG, Edlund K, Marchan R.
Keller M, et al. Among authors: demirci o.
J Exp Clin Cancer Res. 2023 Jan 20;42(1):25. doi: 10.1186/s13046-022-02578-w.
J Exp Clin Cancer Res. 2023.
PMID: 36670508
Free PMC article.